Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20358956 | 1.00 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2RECQLPDE4B | |
| SCHEMBL20358958 | 1.00 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2RECQLPDE4B | |
| SCHEMBL14075552 | 0.91 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2RECQLPDE4B | |
| SCHEMBL12930911 | 0.91 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2RECQLPDE4B | |
| SCHEMBL24707902 | 0.86 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2RECQLPDE4B | |
| SCHEMBL10137666 | 0.86 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2RECQLPDE4B | |
| SCHEMBL25608131 | 0.86 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2RECQLPDE4B | |
| SCHEMBL30342352 | 0.86 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2RECQLPDE4B | |
| SCHEMBL10137667 | 0.86 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2RECQLPDE4B | |
| SCHEMBL10137713 | 0.86 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2RECQLPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206748-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2025-06-26 | — | — | US | disclosed |
| EP-4335497-A2 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. Lundbeck A/S (DK) | 2024-03-13 | — | — | EP | disclosed |
| EP-3865484-B1 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H LUNDBECK AS (DK) | 2023-11-08 | — | — | EP | disclosed |
| EP-3865484-B1 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H LUNDBECK AS (DK) | 2023-11-08 | — | — | EP | disclosed |
| US-20230183255-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2023-06-15 | — | — | US | disclosed |
| US-20230183255-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2023-06-15 | — | — | US | disclosed |
| US-20230183255-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2023-06-15 | — | — | US | disclosed |
| US-11608342-B2 | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases | H. LUNDBECK A/S (DK) | 2023-03-21 | — | — | US | disclosed |
| CN-114903900-A | PDE9 inhibitors for the treatment of peripheral diseases | 伊马拉公司 | 2022-08-16 | — | — | CN | disclosed |
| EP-3865484-A1 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. Lundbeck A/S (DK) | 2021-08-18 | — | — | EP | disclosed |
| US-20200062770-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2020-02-27 | — | — | US | disclosed |
| US-10513524-B2 | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases | H. LUNDBECK A/S (DK) | 2019-12-24 | — | — | US | disclosed |
| US-10513524-B2 | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases | H. LUNDBECK A/S (DK) | 2019-12-24 | — | — | US | disclosed |
| US-20190307754-A1 | PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES | IMARA, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190307754-A1 | PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES | IMARA, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20180194770-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2018-07-12 | — | — | US | disclosed |
| US-20180194770-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2018-07-12 | — | — | US | disclosed |
| US-20180194770-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2018-07-12 | — | — | US | disclosed |
| US-8497383-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120142752-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11608342-B2 | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases | PDE9A, PDE5A, PDE3A | NR1H2 1711/4885USP2 4239/4885SMN1; SMN2 552/4885 |
| US-20250206748-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE5A, PDE3A | NR1H2 1711/4885USP2 4239/4885SMN1; SMN2 552/4885 |
| US-20120142752-A1 | HIV PROTEASE INHIBITORS | SERPINB1, PRSS1, SERPINB6 | NR1H2 2281/4885USP2 2576/4885SMN1; SMN2 4250/4885 |
| US-10513524-B2 | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases | PDE9A, PDE5A, PDE3A | NR1H2 1711/4885USP2 4239/4885SMN1; SMN2 552/4885 |
| US-20190307754-A1 | PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE12, PDE5A | NR1H2 897/4885USP2 3409/4885SMN1; SMN2 399/4885 |
| US-20180194770-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE5A, PDE3A | NR1H2 1711/4885USP2 4239/4885SMN1; SMN2 552/4885 |
| US-20230183255-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE5A, PDE3A | NR1H2 1711/4885USP2 4239/4885SMN1; SMN2 552/4885 |
| US-20200062770-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE5A, PDE3A | NR1H2 1711/4885USP2 4239/4885SMN1; SMN2 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.